Skip to main content
SpringerLink
Log in

Infectious Disease Therapy in the 1990s

Where are we Heading?

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Baba M, Ito M, Shigeta S, De Clerq E. Synergistic antiviral effects of antiherpes compounds and human leukocyte interferon on varicella-zoster virus in vitro. Antimicrobial Agents and Chemotherapy 25: 515–517, 1984

    Article  CAS  PubMed  Google Scholar 

  • Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. New England Journal of Medicine 322: 16–21, 1990

    Article  CAS  PubMed  Google Scholar 

  • Baumgartner JD, Glauser MP, McCutchan JA, Ziegler EJ, Van Melle G, et al. Prevention of gram-negative shock and death in surgical patients by prophylactic antibody to endotoxin core glycolipid. Lancet 2: 59–63, 1985

    Article  CAS  PubMed  Google Scholar 

  • Bermudez LE, Young LS. Tumor necrosis factor alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium aviumcomplex. Journal of Immunology 140: 3006–3013, 1988

    CAS  Google Scholar 

  • Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. New England Journal of Medicine 316: 379–385, 1987

    Article  CAS  PubMed  Google Scholar 

  • Beutler B, Cerami A. The history, properties, and biological effects of cachectin. Biochemistry 27: 7575–7582, 1988

    Article  CAS  PubMed  Google Scholar 

  • Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869–871, 1985

    Article  CAS  PubMed  Google Scholar 

  • Bone RC. Monoclonal antibodies to endotoxin: new allies against sepsis? Journal of the American Medical Association 266: 1125–1126, 1991

    Article  CAS  PubMed  Google Scholar 

  • Bone RC, Fischer Jr CJ, Clemmer TP, Slotman GJ, Metz CA, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. New England Journal of Medicine 317: 653–658, 1987

    Article  CAS  PubMed  Google Scholar 

  • Bonilla MA, Gillio AP, Ruggeiro M, Kernan NA, Brochstein JA, et al. Effect of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. New England Journal of Medicine 320: 1574–1580, 1989

    Article  CAS  PubMed  Google Scholar 

  • Calandra T, Glauser MP, Schellekens J, Verhoef J and the Swiss-Dutch J5 Immunoglobulin Study Group. Treatment of gramnegative septic shock with human IgG antibody to Escherichia coliJ5: a prospective, double-blind randomized trial. Journal of Infectious Diseases 158: 312–319, 1988

    Article  CAS  PubMed  Google Scholar 

  • Chrisp P, Clissold SP. Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immuno-compromised patients with cytomegalovirus retinitis. Drugs 41: 104–129, 1991

    Article  CAS  PubMed  Google Scholar 

  • De Clerq E. Molecular targets of chemotherapeutic agents against the human immunodeficiency virus. In Jackson et al. (Eds) Current topics in infectious diseases and clinical microbiology, Vol 2: Perspectives in anti-infective therapy, pp. 255–267, Friedr. Vieweg & Son, Braunschweig, 1989

    Google Scholar 

  • De Jongh-Leuvenink J, Schellekens J, Verhoef J. Characterization of anticore glycolipid monoclonal antibodies with chemically defined lipopolysaccharides. Infection and Immunity 58: 421–426, 1990

    PubMed  Google Scholar 

  • Editorial. Increase in National Hospital discharge survey rates for septicemia — United States, 1979—1987. Mortality, Morbidity and Weekly Reports 39: 31–34, 1990

    Google Scholar 

  • Erice A, Chou S, Biron KK, Stanat SC, Balfour Jr HH, et al. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. New England Journal of Medicine 320: 289–293, 1989

    Article  CAS  PubMed  Google Scholar 

  • Erlich KS, Mills J, Chatis P, Mertz GJ, Busch DF, et al. Acyclovir resistant herpes simplex virus infection in patients with the acquired immunodeficiency syndrome. New England Journal of Medicine 320: 293–296, 1989

    Article  CAS  PubMed  Google Scholar 

  • Exley AR, Cohen J, Buurman W, Owen R, Lumley J, et al. Monoclonal antibody to TNF in severe septic shock. Lancet 335: 1275–1277, 1990

    Article  CAS  PubMed  Google Scholar 

  • Faulds D, Heel RC. Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 39: 597–638, 1990

    Article  CAS  PubMed  Google Scholar 

  • Girardin E, Graun GE, Dayer JM, Roux-Lombard P, and the J5 Study Group, Lambert PH. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. New England Journal of Medicine 319: 397–400, 1988

    Article  CAS  PubMed  Google Scholar 

  • Golfre G, Milstein C. Preparation of monoclonal antibodies: strategies and procedures. Methods of Enzymology 73: 1–46, 1981

    Google Scholar 

  • Grant SM, Heel RC. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): a review of its pharmacological properties and prospective role in the management of myelosuppression. Drugs 43: in press, 1992

  • Greenman RL, Schein RMH, Martin MA, Wenzel RP, Maclntyre NR, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. Journal of the American Medical Association 266: 1097–1102, 1991

    Article  CAS  PubMed  Google Scholar 

  • Hesse DG, Tracey KJ, Fong Y, Manoque KR, Palladino Jr MA, et al. Cytokine appearance in human endotoxemia and primate bacteremia. Surgery in Gynecology and Obstetrics 166: 147–153, 1988

    CAS  Google Scholar 

  • Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglic A, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. New England Journal of Medicine 315: 1059–1064

  • 1986 International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. New England Journal of Medicine 324: 509–516, 1991

    Article  Google Scholar 

  • Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia IV. Reevaluation of clinical features and treatment of 612 patients. American Journal of Medicine 68: 344–355, 1980

    Article  CAS  PubMed  Google Scholar 

  • Lachman E, Pitsoe SB, Gaffin SL. Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynecological origin Lancet 1: 981–983, 19

  • Lader BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) during prolonged therapy. Science 243: 1731–1734, 1989

    Article  Google Scholar 

  • Langtry HD, Campoli-Richards DM. Zidovudine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 37: 408–450, 1989

    Article  CAS  PubMed  Google Scholar 

  • Lok AS, Wu PC, Lai CL, Leung EKY. Long term follow-up in a randomized controlled trial of recombinant alpha-2-interferon in Chinese patients with chronic hepatitis-B infection. Lancet 2: 298–302, 1988

    Article  CAS  PubMed  Google Scholar 

  • Masuho Y. Human monoclonal antibodies: prospects for use as passive immunotherapy. Serodiagnosis and Immunotherapy in Infectious Diseases 2: 319–340, 1988

    Article  Google Scholar 

  • Mattsby-Baltzer I, Alving CR. Antibodies to lipid A: occurrence in humans. Review of Infectious Diseases 6: 553–557, 1984

    Article  CAS  Google Scholar 

  • Meunier F. Fungal infections in the immunocompromised host. In Rubin RH & Young LS (Eds) Clinical approach to infection in the compromised host, 2nd edition, pp. 193–220, Plenum Medical, New York, 1988

    Chapter  Google Scholar 

  • Meunier F. New methods for delivery of antifungal agents. Review of Infectious Diseases (Suppl.) 11: S1605-S1612, 1989

  • Michie HR, Manoque KR, Spriggs DR, Revhaug A, O’Dwyer S, et al. Detection of circulating tumor necrosis factor for endotoxin administration. New England Journal of Medicine 318: 1481–1486, 1988

    Article  CAS  PubMed  Google Scholar 

  • Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Nusinoff Lehrmann S, et al. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proceedings of the National Academy of Science (USA) 82: 7096–7100, 1985

    Article  CAS  Google Scholar 

  • Morrison DC, Ryan JL. Endotoxins and disease mechanisms. Annual Review of Medicine 38: 417–432, 1987

    Article  CAS  PubMed  Google Scholar 

  • Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proceedings of the National Academy of Science of the USA 81: 6851–6855, 1984

    Article  CAS  Google Scholar 

  • Murray HW. Interferon-gamma, the activated macrophage and host defense against microbial challenge. Annals of Internal Medicine 108: 595–608, 1988

    CAS  PubMed  Google Scholar 

  • Nathan CF, Kaplan G, Levis WR, Nusrat A, Witmer MD, et al. Local and systemic effects of intadermal recombinant interferon-gamma in patients with lepromatous leprosy. New England Journal of Medicine 315: 6–15, 1986

    Article  CAS  PubMed  Google Scholar 

  • Neu HC. New strategies for the 1990’s: antibacterial therapy. International Journal of Antimicrobial Agents 1: 47–50, 1991

    Article  CAS  PubMed  Google Scholar 

  • O’Brien JJ, Campoli-Richards DM. Acyclovir: an updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 37: 233–309, 1989

    Article  PubMed  Google Scholar 

  • Opal SM, Cross AS, Kelly NM, Sadoff JC, Bodmer MW, et al. Efficacy of monoclonal antibodies directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. Journal of Infectious Diseases 161: 1148–1152, 1

    Article  CAS  PubMed  Google Scholar 

  • Parillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, et al. Septic shock in humans: advances in the understanding of pathogenesis/cardiovascular dysfunction and therapy. Annals of Internal Medicine 113: 227–242, 1990

    Google Scholar 

  • Pizzo PA, Young LS. Limitations of current antimicrobial therapy in the immunosuppressed host: looking at both sides of the coin. American Journal of Medicine 76: 101–107, 1984

    Article  CAS  PubMed  Google Scholar 

  • Plosker GL, Goa KL. HA-1A (Human monoclonal antibody against endotoxin): a novel pharmacological approach for the treatment of Gram-negative bacteraemia and septic shock. Drugs 43: in press, 1992

  • Polin RA. Monoclonal antibodies against microorganisms. European Journal of Clinical Microbiology 4: 1–9, 1985

    Article  Google Scholar 

  • Pollack M, Chia JKS, Koles NL, Miller M, Guelde G. Specificity and cross-reacting of monoclonal antibodies reactive with the core and lipid A region of bacterial lipopolysaccharide. Journal of Infectious Diseases 159: 168–188, 1989

    Article  CAS  PubMed  Google Scholar 

  • Rasmussen L, Chen PT, Mullenax JG, Merigan TC. Inhibition of cytomegalovirus replication by 9-(l,3-hydroxy-2-propoxymethyl) guanine alone and in combination with human interferons. Antimicrobial Agents and Chemotherapy 26: 441–445, 1984

    Article  CAS  PubMed  Google Scholar 

  • Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD, et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Annals of Internal Medicine 109: 783–788, 1988

    CAS  PubMed  Google Scholar 

  • Reed SG, Nathan CF, Pihl DL, Rodricks P, Shanebeck K, et al. Recombinant granulocyte/-macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzeiand release of hydrogen peroxide. Journal of Experimental Medicine 166: 1734–1746, 1987

    Article  CAS  PubMed  Google Scholar 

  • Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 332: 323–327, 1988

    Article  CAS  PubMed  Google Scholar 

  • Ruef F, Coleman DL. Granulocyte-macrophage colony stimulating factor: pleiotropic cytokine with potential clinical usefulness. Reviews of Infectious Diseases 12: 42–62, 1990

    Article  Google Scholar 

  • Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Safety 5: 94–108, 1990

    Article  CAS  PubMed  Google Scholar 

  • Schellekens J, Benne CA, De Zeeuw GR, Rozenberg-Arska M, Verhoef J. Naturally occurring IgG and IgM antibodies to gramnegative bacteria and lipopolysaccharides in human sera. Serodiagnosis and Immunotherapy in Infectious Diseases 2: 433–444, 1988

    Article  Google Scholar 

  • Shenep JL, Barton RP, Mogan KA. Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental gram-negative bacterial sepsis. Journal of Infectious Diseases 151: 1012–1018, 1985

    Article  CAS  PubMed  Google Scholar 

  • Shenep JL, Flynn PM, Barrett FF, Stidham GL, Westenkirchner DF. Serial quantitation of endotoxin and bacteremia during therapy for gram-negative bacterial sepsis. Journal of Infectious Diseases 157: 565–568, 1988

    Article  CAS  PubMed  Google Scholar 

  • Smith DH, Byrn RA, Masters SA, Gregory T, Groopman JE, et al. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 238: 1704–1707, 1987

    Article  CAS  PubMed  Google Scholar 

  • Talmadge JE, Tribble H, Pennington R, Bowersox O, Schneider MA, et al. Protective, restorative, and therapeutic properties of recombinant colony-stimulating factors. Blood 73: 2093–2103, 1989

    CAS  PubMed  Google Scholar 

  • Teng NNH, Kaplan HS, Hebert JM, Moore C, Douglas H, et al. Protection against gram-negative bacteremia and endotoxin with human monoclonal IgM antibodies. Proceedings of the National Academy of Science of the USA 82: 1790–1794, 1985

    Article  CAS  Google Scholar 

  • Todd PA, Goa KL. Interferon Gamma-1b: a review of its pharmacology and therapeutic potential in chronic granulomatous disease. Drugs 43: in press, 1992

  • Tracey KJ, Fong Y, Hesse DG, Manoque KR, Lee AT, et al. Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330: 662–664, 1987

    Article  CAS  PubMed  Google Scholar 

  • Urbaschek R, Urbaschek B. Tumor necrosis factor and interleukin-1 as mediators of endotoxin-induced beneficial effects. Reviews of Infectious Diseases 9 (Suppl.): S607–S615, 1987

    Article  CAS  PubMed  Google Scholar 

  • Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, Mc-Credie K, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. New England Journal of Medicine 317: 1545–1552

  • 1987Veterans Administration Systemic Sepsis Cooperation Study Group. Effect of high dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. New England Journal of Medicine 317: 659–665, 1987

    Article  Google Scholar 

  • Waage A, Halstensen A, Espevik T. Association between tumor necrosis factor serum and total outcome in patients with meningococcal disease. Lancet 1: 355–357, 1987

    Article  CAS  PubMed  Google Scholar 

  • Weiser WY, Van Niel A, Clark SC, David JR, Remold HG. Recombinant human granulocyte/macrophage colony stimulating factor activates intracellular killing of Leishmania donovaniby human monocyte derived macrophages. Journal of Experimental Medicine 166: 1436–1446, 1987

    Article  CAS  PubMed  Google Scholar 

  • Woodford N, Johnson AP, George RC. Detection of glycopeptide resistance in clinical isolates of Gram-positive bacteria. Journal of Antimicrobial Chemotherapy 28: 483–490, 1991

    Article  CAS  PubMed  Google Scholar 

  • Young LS. Management of infections in leukemia and lymphoma. In Rubin RH & Young LS (Eds) Clinical approach to infection in the compromised host, pp. 467–502, New York, Plenum Press, 1988

    Chapter  Google Scholar 

  • Young LS, Gascon R, Alam S, Bermudez LE. Monoclonan antibodies for treatment of gram-negative infections. Reviews of Infectious Diseases 11 (Suppl. 7): S1564–S1571; 1989

    Article  PubMed  Google Scholar 

  • Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. New England Journal of Medicine 307: 1225–1230, 1982

    Article  CAS  PubMed  Google Scholar 

  • Ziegler EJ, Fisher Jr CJ, Spring CL, Straube RC, Sadoff JC, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind placebo controlled trial. New England Journal of Medicine 324: 429–436, 1991

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Microbiology and Laboratory of Infectious Diseases, University Hospital Utrecht, HP G 04.515, P.O. Box 85500, 3508, GA Utrecht, The Netherlands

    M. Rozenberg-Arska & M. R. Visser

Authors
  1. M. Rozenberg-Arska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. R. Visser
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rozenberg-Arska, M., Visser, M.R. Infectious Disease Therapy in the 1990s. Drugs 43, 629–636 (1992). https://doi.org/10.2165/00003495-199243050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199243050-00001

Keywords

Search

Navigation